Thomas S Griffith

List of Publications by Year
in descending order

149	12,454	41627 51	30277 107
papers	citations	h-index	g-index

155	155	155	15105
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs. Bioorganic and Medicinal Chemistry Letters, 2022, 59, 128548.	1.0	4
2	Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes. Molecular Therapy, 2021, 29, 149-161.	3.7	10
3	Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation. Gene Therapy, 2021, 28, 130-141.	2.3	9
4	Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Scientific Reports, 2021, 11, 3346.	1.6	17
5	Prolonged Reactive Oxygen Species Production following Septic Insult. ImmunoHorizons, 2021, 5, 477-488.	0.8	14
6	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. Human Gene Therapy, 2021, 32, 541-562.	1.4	9
7	Sepsis, Cytokine Storms, and Immunopathology: The Divide between Neonates and Adults. ImmunoHorizons, 2021, 5, 512-522.	0.8	14
8	Severity of Sepsis Determines the Degree of Impairment Observed in Circulatory and Tissue-Resident Memory CD8 T Cell Populations. Journal of Immunology, 2021, 207, 1871-1881.	0.4	10
9	Sepsis and multiple sclerosis: Causative links and outcomes. Immunology Letters, 2021, 238, 40-46.	1.1	5
10	NK Cellâ€“Derived IL-10 Supports Host Survival during Sepsis. Journal of Immunology, 2021, 206, 1171-1180.	0.4	19
11	Autoimmunity Increases Susceptibility to and Mortality from Sepsis. ImmunoHorizons, 2021, 5, 844-854.	0.8	3
12	Sepsis leads to lasting changes in phenotype and function of memory CD8 T cells. ELife, 2021, 10, .	2.8	19
13	Inducing Experimental Polymicrobial Sepsis by Cecal Ligation and Puncture. Current Protocols in Immunology, 2020, 131, e110.	3.6	25
14	TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. Molecular Pharmaceutics, 2020, 17, 2109-2124.	2.3	28
15	New Insights into the Immune System Using Dirty Mice. Journal of Immunology, 2020, 205, 3-11.	0.4	59
16	Worry and FRET: ROS Production Leads to Fluorochrome Tandem Degradation and impairs Interpretation of Flow Cytometric Results. Immunity, 2020, 52, 419-421.	6.6	6
17	Exploiting antibody biology for the treatment of cancer. Immunotherapy, 2020, 12, 255-267.	1.0	7
18	CD4 T Cell Responses and the Sepsis-Induced Immunoparalysis State. Frontiers in Immunology, 2020, 11, 1364.	2.2	83

#	Article	IF	Citations
19	Polymicrobial Sepsis Impairs Antigen-Specific Memory CD4 T Cell-Mediated Immunity. Frontiers in Immunology, 2020, 11, 1786.	2.2	18
20	CD8⁺ T cells mediate ultraviolet Aâ€induced immunomodulation in a model of extracorporeal photochemotherapy. European Journal of Immunology, 2020, 50, 725-735.	1.6	6
21	Sepsis impedes EAE disease development and diminishes autoantigen-specific naive CD4 T cells. ELife, 2020, 9, .	2.8	16
22	Microbial Exposure Enhances Immunity to Pathogens Recognized by TLR2 but Increases Susceptibility to Cytokine Storm through TLR4 Sensitization. Cell Reports, 2019, 28, 1729-1743.e5.	2.9	74
23	A wild microbiome improves mouse modeling of the human immune response. Lab Animal, 2019, 48, 337-338.	0.2	5
24	Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses. Journal of Virology, 2019, 93, .	1.5	11
25	Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cellâ€“Mediated Antitumor Immunity. Journal of Immunology, 2019, 203, 725-735.	0.4	21
26	Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival. Journal of Immunology, 2019, 202, 2843-2848.	0.4	20
27	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nature Medicine, 2019, 25, 141-151.	15.2	539
28	Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 715-724.	1.3	38
29	Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Molecular Pharmaceutics, 2019, 16, 1200-1210.	2.3	30
30	HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. Gene Therapy, 2018, 25, 269-283.	2.3	12
31	Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials, 2018, 164, 38-53.	5.7	133
32	Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes. Human Gene Therapy, 2018, 29, 802-815.	1.4	16
33	Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. Cell Death and Disease, 2018, 8, e2535-e2535.	2.7	9
34	Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy. Nanoscale, 2018, 10, 20851-20862.	2.8	59
35	Polymicrobial Sepsis Chronic Immunoparalysis Is Defined by Diminished Ag-Specific T Cell-Dependent B Cell Responses. Frontiers in Immunology, 2018, 9, 2532.	2.2	48
36	Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections. PLoS Pathogens, 2018, 14, e1007405.	2.1	46

#	Article	IF	Citations
37	Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells. ACS Nano, 2018, 12, 6563-6576.	7.3	24
38	Cutting Edge: Elevated Leptin during Diet-Induced Obesity Reduces the Efficacy of Tumor Immunotherapy. Journal of Immunology, 2018, 201, 1837-1841.	0.4	53
39	Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity. Journal of Immunology, 2018, 200, 1543-1553.	0.4	143
40	The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer. Immunotherapy, 2017, 9, 1005-1018.	1.0	2
41	Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8. ACS Medicinal Chemistry Letters, 2017, 8, 1148-1152.	1.3	32
42	A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies. Journal of Visualized Experiments, 2017, , .	0.2	16
43	TRAIL deletion prevents liver inflammation but not adipose tissue inflammation during murine dietâ€induced obesity. Hepatology Communications, 2017, 1, 648-662.	2.0	33
44	Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of disease. Experimental Biology and Medicine, 2017, 242, 127-139.	1.1	51
45	The current status of immunobased therapies for metastatic renal-cell carcinoma. ImmunoTargets and Therapy, 2017, Volume 6, 83-93.	2.7	14
46	Polymicrobial sepsis impairs bystander recruitment of effector cells to infected skin despite optimal sensing and alarming function of skin resident memory CD8 T cells. PLoS Pathogens, 2017, 13, e1006569.	2.1	47
47	Focal Therapy for Prostate Cancer: A Molecular Biology Approach with TRAIL. Current Clinical Urology, 2017, , 347-354.	0.0	0
48	CD8 T Cellâ€“Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers, 2016, 8, 71.	1.7	8
49	Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity. Critical Reviews in Immunology, 2016, 36, 57-74.	1.0	55
50	Gut Microbial Membership Modulates CD4 T Cell Reconstitution and Function after Sepsis. Journal of Immunology, 2016, 197, 1692-1698.	0.4	31
51	Polymicrobial Sepsis Diminishes Dendritic Cell Numbers and Function Directly Contributing to Impaired Primary CD8 T Cell Responses In Vivo. Journal of Immunology, 2016, 197, 4301-4311.	0.4	48
52	Triptolide enhances the tumoricidal activity of <scp>TRAIL</scp> against renal cell carcinoma. FEBS Journal, 2015, 282, 4747-4765.	2.2	15
53	Alterations in Antigen-Specific Naive CD4 T Cell Precursors after Sepsis Impairs Their Responsiveness to Pathogen Challenge. Journal of Immunology, 2015, 194, 1609-1620.	0.4	55
54	Polymicrobial Sepsis Increases Susceptibility to Chronic Viral Infection and Exacerbates CD8+ T Cell Exhaustion. Journal of Immunology, 2015, 195, 116-125.	0.4	48

#	Article	IF	Citations
55	Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2015, 11, 1612-1620.	1.4	16
56	Therapeutic applications of TRAIL receptor agonists in cancer and beyond. , 2015, 155, 117-131.		67
57	The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse. Journal of Immunology, 2015, 194, 5926-5936.	0.4	40
58	Immunosuppression after Sepsis: Systemic Inflammation and Sepsis Induce a Loss of NaÃ¨ve T-Cells but No Enduring Cell-Autonomous Defects in T-Cell Function. PLoS ONE, 2014, 9, e115094.	1.1	52
59	Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic pathways in cancer immunosurveillance: molecular mechanisms and prospects for therapy. Research and Reports in Biochemistry, 2014, , 1.	1.6	3
60	GLP-1-mediated gene therapy approaches for diabetes treatment. Expert Reviews in Molecular Medicine, 2014, 16, e7.	1.6	14
61	Intravascular staining for discrimination of vascular and tissue leukocytes. Nature Protocols, 2014, 9, 209-222.	5.5	612
62	Polymicrobial Sepsis Alters Antigen-Dependent and -Independent Memory CD8 T Cell Functions. Journal of Immunology, 2014, 192, 3618-3625.	0.4	58
63	Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8Î± dendritic cells. Cancer Immunology, Immunotherapy, 2014, 63, 685-697.	2.0	19
64	Cellular Inhibitor of Apoptosis Protein cIAP2 Protects against Pulmonary Tissue Necrosis during Influenza Virus Infection to Promote Host Survival. Cell Host and Microbe, 2014, 15, 23-35.	5.1	141
65	Impact of sepsis on CD4 T cell immunity. Journal of Leukocyte Biology, 2014, 96, 767-777.	1.5	128
66	CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunology, Immunotherapy, 2014, 63, 1213-1227.	2.0	32
67	Minimal changes in the systemic immune response after nephrectomy of localized renal masses11This work was supported by the University of Iowa Carver College of Medicine/Department of Urology Investigator Start-up Funds, NIH Grant CA181088-01 (to L.A.N.), and NIH Grant CA109446 (to T.S.G.).. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 589-600.	0.8	19
68	PMN and anti-tumor immunityâ€"The case of bladder cancer immunotherapy. Seminars in Cancer Biology, 2013, 23, 183-189.	4.3	38
69	Sustained and Incomplete Recovery of Naive CD8+ T Cell Precursors after Sepsis Contributes to Impaired CD8+ T Cell Responses to Infection. Journal of Immunology, 2013, 190, 1991-2000.	0.4	73
70	Clinical utility of insulin and insulin analogs. Islets, 2013, 5, 67-78.	0.9	40
71	T-Cell-Mediated Immunity and the Role of TRAIL in Sepsis-Induced Immunosuppression. Critical Reviews in Immunology, 2013, 33, 23-40.	1.0	43
72	Diet-Induced Obesity Alters Dendritic Cell Function in the Presence and Absence of Tumor Growth. Journal of Immunology, 2012, 189, 1311-1321.	0.4	94

#	Article	IF	Citations
73	Therapeutic potential of VIP vs PACAP in diabetes. Journal of Molecular Endocrinology, 2012, 49, R157-R167.	1.1	41
74	Activation of systemic antitumor immunity via TRAIL-induced apoptosis. OncoImmunology, 2012, 1, 1178-1180.	2.1	4
75	TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. Journal of Experimental Medicine, 2012, 209, 1937-1952.	4.2	79
76	Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy. PLoS ONE, 2012, 7, e31085.	1.1	46
77	Cell Death in the Maintenance and Abrogation of Tolerance: The Five Ws of Dying Cells. Immunity, 2011, 35, 456-466.	6.6	86
78	Description of a Novel Murine Model for Ileocystoplasty and Early Histologic Changes. Scientific World Journal, The, 2011, 11, 1325-1331.	0.8	2
79	Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 13-26.	2.2	28
80	Tracing of islet graft survival by way of in vivo fluorescence imaging. Diabetes/Metabolism Research and Reviews, 2011, 27, 575-583.	1.7	11
81	Immune Unresponsiveness to Secondary Heterologous Bacterial Infection after Sepsis Induction Is TRAIL Dependent. Journal of Immunology, 2011, 187, 2148-2154.	0.4	56
82	The Magnitude of the T Cell Response to a Clinically Significant Dose of Influenza Virus Is Regulated by TRAIL. Journal of Immunology, 2011, 187, 4581-4588.	0.4	36
83	Systemic Immunological Tolerance to Ocular Antigens Is Mediated by TRAIL-Expressing CD8+ T Cells. Journal of Immunology, 2011, 186, 791-798.	0.4	24
84	The Plasticity of Regulatory T Cell Function. Journal of Immunology, 2011, 187, 4987-4997.	0.4	58
85	Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. Cancers, 2011, 3, 603-620.	1.7	11
86	TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion. Journal of Leukocyte Biology, 2010, 88, 1217-1225.	1.5	18
87	Sepsis-Induced Apoptosis Leads to Active Suppression of Delayed-Type Hypersensitivity by CD8+ Regulatory T Cells through a TRAIL-Dependent Mechanism. Journal of Immunology, 2010, 184, 6766-6772.	0.4	63
88	Micro-recanalization in a biodegradable graft for reconstruction of the vas deferens is enhanced by sildenafil citrate. Asian Journal of Andrology, 2010, 12, 814-818.	0.8	1
89	Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Current Opinion in Investigational Drugs, 2010, 11, 688-98.	2.3	22
90	Adenovirus-Mediated TRAIL Gene (Ad5hTRAIL) Delivery into Pancreatic Islets Prolongs Normoglycemia in Streptozotocin-Induced Diabetic Rats. Human Gene Therapy, 2009, 20, 1177-1189.	1.4	31

#	Article	IF	Citations
91	Activation-Induced CD154 Expression Abrogates Tolerance Induced by Apoptotic Cells. Journal of Immunology, 2009, 183, 6114-6123.	0.4	24
92	TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. European Journal of Pharmacology, 2009, 625, 63-72.	1.7	163
93	The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmetteâ€“GuÃ©rin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer and Metastasis Reviews, 2009, 28, 345-353.	2.7	44
94	Early microrecanalization of vas deferens following biodegradable graft implantation in bilaterally vasectomized rats. Asian Journal of Andrology, 2009, 11, 373-378.	0.8	6
95	The Use of Immunofluorescence in Microdissection Testicular Sperm Extraction. Journal of Andrology, 2009, 30, 548-551.	2.0	10
96	TRAIL-Deficient Mice Exhibit Delayed Regression of Retinal Neovascularization. American Journal of Pathology, 2009, 175, 2697-2708.	1.9	17
97	High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients. Pancreas, 2009, 38, 154-160.	0.5	30
98	TRAIL Gene Therapy: From Preclinical Development to Clinical Application. Current Gene Therapy, 2009, 9, 9-19.	0.9	84
99	Induction of Tumor Cell Apoptosis by TRAIL Gene Therapy. Methods in Molecular Biology, 2009, 542, 315-334.	0.4	4
100	Molecular mechanisms of death ligandâ€mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes. Journal of Cellular Biochemistry, 2008, 104, 710-720.	1.2	27
101	Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells. Human Immunology, 2008, 69, 634-646.	1.2	24
102	Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 158-165.	0.8	33
103	Role of neutrophils in BCG immunotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 341-345.	0.8	100
104	TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. Journal of Leukocyte Biology, 2008, 83, 621-629.	1.5	26
105	CD8 T Cells Utilize TRAIL to Control Influenza Virus Infection. Journal of Immunology, 2008, 181, 4918-4925.	0.4	176
106	High Levels of Endogenous Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression Correlate With Increased Cell Death in Human Pancreas. Pancreas, 2008, 36, 385-393.	0.5	27
107	Apoptotic Cells Induce Tolerance by Generating Helpless CD8+ T Cells That Produce TRAIL. Journal of Immunology, 2007, 178, 2679-2687.	0.4	81
108	Identification of the Mycobacterial Subcomponents Involved in the Release of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand from Human Neutrophils. Infection and Immunity, 2007, 75, 1265-1271.	1.0	39

#	Article	IF	Citations
109	Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy. Cancer Research, 2007, 67, 11980-11990.	0.4	45
110	Cytomegalovirus and the role of interferon in the expression of tumor necrosis factorâ€“related apoptosis-inducing ligand in the placenta. American Journal of Obstetrics and Gynecology, 2007, 197, 608.e1-608.e6.	0.7	8
111	Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 561-571.	2.2	45
112	Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunologic Research, 2007, 39, 79-93.	1.3	39
113	Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. Journal of Pediatric Surgery, 2006, 41, 1431-1440.	0.8	29
114	Neisseria gonorrhoeae delays the onset of apoptosis in polymorphonuclear leukocytes. Cellular Microbiology, 2006, 8, 1780-1790.	1.1	49
115	A vision of cell death: Fas ligand and immune privilege 10 years later. Immunological Reviews, 2006, 213, 228-238.	2.8	101
116	Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-Î± combination therapy. International Journal of Cancer, 2006, 119, 2632-2641.	2.3	15
117	TRAIL Deficiency Delays, but Does Not Prevent, Erosion in the Quality of â€œHelplessâ€•Memory CD8 T Cells. Journal of Immunology, 2006, 177, 999-1006.	0.4	56
118	Histone Deacetylase Inhibitors Modulate the Sensitivity of Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligandâ€“Resistant Bladder Tumor Cells. Cancer Research, 2006, 66, 499-507.	0.4	80
119	CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature, 2005, 434, 88-93.	13.7	547
120	Depsipeptide (FR901228) Enhances the Cytotoxic Activity of TRAIL by Redistributing TRAIL Receptor to Membrane Lipid Rafts. Molecular Therapy, 2005, 11, 542-552.	3.7	81
121	Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. Journal of Leukocyte Biology, 2005, 77, 378-387.	1.5	90
122	Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biology and Therapy, 2005, 4, 1104-1112.	1.5	59
123	Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guèrin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood, 2005, 106, 3474-3482.	0.6	112
124	Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation. Journal of Immunology, 2004, 173, 892-899.	0.4	95
125	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Cancer Research, 2004, 64, 3386-3390.	0.4	167
126	Inhibition of the NF-ÎºB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Therapy, 2004, 11, 681-690.	2.2	54

#	Article	IF	Citations
127	Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Experimental Hematology, 2004, 32, 1073-1081.	0.2	38
128	The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemotherapy and Pharmacology, 2003, 52, 175-184.	1.1	14
129	Apoptosis, tolerance, and regulatory T cells - old wine, new wineskins. Immunological Reviews, 2003, 193, 111-123.	2.8	55
130	Structure/Function Analysis of the Murine CD95L Promoter Reveals the Identification of a Novel Transcriptional Repressor and Functional CD28 Response Element. Journal of Biological Chemistry, 2003, 278, 35950-35958.	1.6	22
131	Plasmacytoid Dendritic Cell-Derived IFN-Î± Induces TNF-Related Apoptosis-Inducing Ligand/Apo-2L-Mediated Antitumor Activity by Human Monocytes Following CpG Oligodeoxynucleotide Stimulation. Journal of Immunology, 2003, 171, 212-218.	0.4	67
132	Uptake of Apoptotic Antigen-Coupled Cells by Lymphoid Dendritic Cells and Cross-Priming of CD8+ T Cells Produce Active Immune Unresponsiveness. Journal of Immunology, 2002, 168, 5589-5595.	0.4	174
133	TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site. Journal of Immunology, 2002, 169, 4739-4744.	0.4	95
134	Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Research, 2002, 62, 3093-9.	0.4	60
135	Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research, 2002, 62, 7170-4.	0.4	201
136	Regulation of Fas Ligand-Induced Apoptosis by TNF. Journal of Immunology, 2001, 167, 3049-3056.	0.4	62
137	Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses. Journal of the National Cancer Institute, 2001, 93, 998-1007.	3.0	28
138	Suppression of Tumor Growth Following Intralesional Therapy with TRAIL Recombinant Adenovirus. Molecular Therapy, 2001, 4, 257-266.	3.7	90
139	Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis. Journal of Immunology, 2000, 165, 2886-2894.	0.4	184
140	Tumoricidal activity of tumor necrosis factorâ€“related apoptosisâ€“inducing ligand in vivo. Nature Medicine, 1999, 5, 157-163.	15.2	2,377
141	Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factorâ€“related Cytokine, TRAIL. Journal of Experimental Medicine, 1999, 189, 1343-1354.	4.2	442
142	Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligand (Trail). Journal of Experimental Medicine, 1999, 190, 1155-1164.	4.2	369
143	TRAIL: a molecule with multiple receptors and control mechanisms. Current Opinion in Immunology, 1998, 10, 559-563.	2.4	436
144	Inducible Nonlymphoid Expression of Fas Ligand Is Responsible for Superantigen-Induced Peripheral Deletion of T Cells. Immunity, 1998, 9, 711-720.	6.6	145

#	Article	IF	Citations
145	Antiinflammatory Effects of CD95 Ligand (FasL)-induced Apoptosis. Journal of Experimental Medicine, 1998, 188, 887-896.	4.2	208
146	A vision of cell death: insights into immune privilege. Immunological Reviews, 1997, 156, 167-184.	2.8	167
147	Cell death and the immune response: a lesson from the privileged. Journal of Clinical Immunology, 1997, 17, 1-10.	2.0	15
148	CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance. Immunity, 1996, 5, 7-16.	6.6	366
149	The immune response and the eye. TCR Â-chain related molecules regulate the systemic immunity to antigen presented in the eye. International Immunology, 1995, 7, 1617-1625.	1.8	29